Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Unity Biotechnology, Inc. - Common Stock (NQ:UBX)

0.2001 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Unity Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Analyst Ratings for Unity Biotechnology
Via Benzinga
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 26, 2023
Via Benzinga
The Latest Analyst Ratings for Unity Biotechnology
Via Benzinga
Where Unity Biotechnology Stands With Analysts
Via Benzinga
Recap: Unity Biotechnology Q1 Earnings
Via Benzinga
Where Unity Biotechnology Stands With Analysts
Via Benzinga
Expert Ratings for Unity Biotechnology
Via Benzinga
UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)
From Unity Biotechnology, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2023
Via Benzinga
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
Unity Touts Positive Data From Diabetic Macular Edema Study, Plans Head-To-Head Study With Regeneron's Eylea
Via Benzinga
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
Program Update with retinal expert and senior clinical advisor Robert B. Bhisitkul, M.D., Ph.D., to be held on Monday, April 24 at 5:00 a.m. PT/8:00 a.m. ET 
From Unity Biotechnology, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 81 companies hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 76 companies set new 52-week lows. 
Via Benzinga
Why Shift Technologies Shares Are Trading Lower By 15%; Here Are 20 Stocks Moving Premarket
Gainers LogicMark, Inc. (NASDAQ: LGMK) shares rose 36.7% to $0.1914 in pre-market trading after the company reported strong revenue and margin growth for the year ended 2022. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday, 95 stocks hit new 52-week lows. 
Via Benzinga
Nasdaq Edges Lower; Unity Biotechnology Shares Plummet
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading lower on Monday. The Dow traded up 0.91% to 32,530.40 while the NASDAQ fell 0.09% to 11,813.90. The S&P 500, also... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 89 stocks made new 52-week lows. 
Via Benzinga
Why Is Codiak BioSciences (CDAK) Stock Down 52% Today?
Codiak BioSciences (CDAK) stock is falling hard on Monday after the company announced plans for an asset sale via a Chapter 11 bankruptcy. 
Via InvestorPlace
Gold Drops Over 1%; First Citizens BancShares Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Monday. The Dow traded up 0.42% to 32,372.55 while the NASDAQ rose 0.01% to 11,825.46. The S&P 500, also... 
Via Benzinga
Why Is Unity Biotechnology (UBX) Stock Down 52% Today?
Unity Biotechnology (UBX) stock is taking a beating on Monday after revealing results from its Phase 2 clinical trial of UBX1325. 
Via InvestorPlace
UNITY Biotechnology's Wet AMD Candidate Flunks On Non-Inferiority Threshold Compared To Regeneron's Drug
UNITY Biotechnology Inc (NASDAQ: UBX) announced results from Part A of the Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD) who were not achieving optimum... 
Via Benzinga
US Stocks Open Higher; Dow Rises 200 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining around 200 points on Monday. Following the market opening Monday, the Dow traded up 0.64% to 32,443.64 while the NASDAQ rose 0.20% to... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.